Structured Review

Cayman Chemical n 6 methyl ester
N 6 Methyl Ester, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n 6 methyl ester/product/Cayman Chemical
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
n 6 methyl ester - by Bioz Stars, 2020-09
93/100 stars

Related Products / Commonly Used Together

c22
supelco 37 fame mix
n-3 methyl ester

Images

Related Articles

other:

Article Title: Polyunsaturated fatty acids promote Plasmodium falciparum gametocytogenesis
Article Snippet: Identification of fatty acid methyl ester was based on the retention time by comparing with a standard mixture (Supelco 37-FAME Mix, Sigma-Aldrich), C22:5 n-6 methyl ester (Nu-Chek Prep, Inc., Elysian, MN, USA), C22:5 n-3 methyl ester (Sigma-Aldrich) and C22:4 n-6 methyl ester (Cayman, Ann Arbor, MI, USA).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Cayman Chemical f ibmx
    LATS-BS can be used to measure LATS activity in vitro and in vivo. a LATS-BS can be used to assess LATS activity in different cell lines. LATS-BS was transfected alone or together with LATS2-FLAG into HEK293, MDA-MB231, or A549 cells. Biosensor activity was measured by luciferase assay or BLI of live cells ( n = 3). For BLI, data were heat-mapped (red signal denotes an increase in LATS-BS activity, whereas blue indicates a decrease). b The LATS-BS responds to cell confluency. LATS-BS or pGL3-control were transfected into HEK293 at different confluencies. After 48 h, biosensor activity was determined by luciferase assay using cell lysate (top) or bioluminescent imaging (BLI) of live cells (bottom) ( n = 3). c , d LATS-BS is inhibited by LPA ( c ) and activated by <t>forskolin</t> ( d ). LATS-BS or pGL3-control were transfected into HEK293. Cells were treated with increasing concentrations of LPA for 1 h or with forskolin for 30 min before luciferase assay and BLI ( n = 3). e LATS-BS responds to drug treatments regulating Hippo signaling. HEK293 were transfected with LATS-BS and treated with the following: PI3K inhibitor 1 (GDC0941), 10 μM for 4 h; PDK inhibitor (GSK2334470), 10 μM for 4 h; EGF, 100 ng ml −1 for 1 h; Insulin, 10 μg ml −1 for 1 h; <t>F/IBMX</t> (Forskolin/IBMX), 10 μM Forskolin/100 μM IBMX for 1 h; PI3K inhibitor 2 (LY294002), 10 μM for 4 h; LPA, 10 μM for 1 h; Sphin gosine1-phosphophate (S1P), 1 μM for 1 h; 12- O -tetradecanoylphorbol-13-acetate (TPA), 5 nM for 1 h; 2-deoxy glucose, 25 mM for 1 h. Biosensor activity was determined by luciferase assay or BLI of live cells ( n = 3). f , g LATS-BS can be used to observe LATS activity under the microscope. LATS-BS was stably overexpressed in A549 and MDA-MB231. Cells were imaged using LV200 BLI. Images in g are higher magnification of images in f . Scale bar represents 100 μm ( f ) or 20 μm ( g ). h LATS-BS can be used to determine LATS activity in vivo. HEK293 were transfected with LATS-BS. Cells were injected into the mammary fat pad of immunocompromised mice. After 48 h, BLI was performed. Data are represented as mean ± SD
    F Ibmx, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/f ibmx/product/Cayman Chemical
    Average 92 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    f ibmx - by Bioz Stars, 2020-09
    92/100 stars
      Buy from Supplier

    94
    Cayman Chemical bml 111
    <t>BML-111</t> decreased TGF-β1-induced NIH3T3 cell α-SMA expression in a dose-dependent manner. (A) NIH3T3 cells express rs1 and (B) FPR2. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (1, 10, 100, 200 and 500 nM) for 30 min and then treated with TGF-β1 (5 ng/ml) for 24 h. (C) The expression of α-SMA was assessed using western blotting and (D) quantified. Similar results were obtained from at least 3 sections. Data are expressed as the mean ± standard deviation. # P
    Bml 111, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bml 111/product/Cayman Chemical
    Average 94 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    bml 111 - by Bioz Stars, 2020-09
    94/100 stars
      Buy from Supplier

    93
    Cayman Chemical n 6 methyl ester
    <t>BML-111</t> decreased TGF-β1-induced NIH3T3 cell α-SMA expression in a dose-dependent manner. (A) NIH3T3 cells express rs1 and (B) FPR2. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (1, 10, 100, 200 and 500 nM) for 30 min and then treated with TGF-β1 (5 ng/ml) for 24 h. (C) The expression of α-SMA was assessed using western blotting and (D) quantified. Similar results were obtained from at least 3 sections. Data are expressed as the mean ± standard deviation. # P
    N 6 Methyl Ester, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n 6 methyl ester/product/Cayman Chemical
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    n 6 methyl ester - by Bioz Stars, 2020-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    LATS-BS can be used to measure LATS activity in vitro and in vivo. a LATS-BS can be used to assess LATS activity in different cell lines. LATS-BS was transfected alone or together with LATS2-FLAG into HEK293, MDA-MB231, or A549 cells. Biosensor activity was measured by luciferase assay or BLI of live cells ( n = 3). For BLI, data were heat-mapped (red signal denotes an increase in LATS-BS activity, whereas blue indicates a decrease). b The LATS-BS responds to cell confluency. LATS-BS or pGL3-control were transfected into HEK293 at different confluencies. After 48 h, biosensor activity was determined by luciferase assay using cell lysate (top) or bioluminescent imaging (BLI) of live cells (bottom) ( n = 3). c , d LATS-BS is inhibited by LPA ( c ) and activated by forskolin ( d ). LATS-BS or pGL3-control were transfected into HEK293. Cells were treated with increasing concentrations of LPA for 1 h or with forskolin for 30 min before luciferase assay and BLI ( n = 3). e LATS-BS responds to drug treatments regulating Hippo signaling. HEK293 were transfected with LATS-BS and treated with the following: PI3K inhibitor 1 (GDC0941), 10 μM for 4 h; PDK inhibitor (GSK2334470), 10 μM for 4 h; EGF, 100 ng ml −1 for 1 h; Insulin, 10 μg ml −1 for 1 h; F/IBMX (Forskolin/IBMX), 10 μM Forskolin/100 μM IBMX for 1 h; PI3K inhibitor 2 (LY294002), 10 μM for 4 h; LPA, 10 μM for 1 h; Sphin gosine1-phosphophate (S1P), 1 μM for 1 h; 12- O -tetradecanoylphorbol-13-acetate (TPA), 5 nM for 1 h; 2-deoxy glucose, 25 mM for 1 h. Biosensor activity was determined by luciferase assay or BLI of live cells ( n = 3). f , g LATS-BS can be used to observe LATS activity under the microscope. LATS-BS was stably overexpressed in A549 and MDA-MB231. Cells were imaged using LV200 BLI. Images in g are higher magnification of images in f . Scale bar represents 100 μm ( f ) or 20 μm ( g ). h LATS-BS can be used to determine LATS activity in vivo. HEK293 were transfected with LATS-BS. Cells were injected into the mammary fat pad of immunocompromised mice. After 48 h, BLI was performed. Data are represented as mean ± SD

    Journal: Nature Communications

    Article Title: A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis

    doi: 10.1038/s41467-018-03278-w

    Figure Lengend Snippet: LATS-BS can be used to measure LATS activity in vitro and in vivo. a LATS-BS can be used to assess LATS activity in different cell lines. LATS-BS was transfected alone or together with LATS2-FLAG into HEK293, MDA-MB231, or A549 cells. Biosensor activity was measured by luciferase assay or BLI of live cells ( n = 3). For BLI, data were heat-mapped (red signal denotes an increase in LATS-BS activity, whereas blue indicates a decrease). b The LATS-BS responds to cell confluency. LATS-BS or pGL3-control were transfected into HEK293 at different confluencies. After 48 h, biosensor activity was determined by luciferase assay using cell lysate (top) or bioluminescent imaging (BLI) of live cells (bottom) ( n = 3). c , d LATS-BS is inhibited by LPA ( c ) and activated by forskolin ( d ). LATS-BS or pGL3-control were transfected into HEK293. Cells were treated with increasing concentrations of LPA for 1 h or with forskolin for 30 min before luciferase assay and BLI ( n = 3). e LATS-BS responds to drug treatments regulating Hippo signaling. HEK293 were transfected with LATS-BS and treated with the following: PI3K inhibitor 1 (GDC0941), 10 μM for 4 h; PDK inhibitor (GSK2334470), 10 μM for 4 h; EGF, 100 ng ml −1 for 1 h; Insulin, 10 μg ml −1 for 1 h; F/IBMX (Forskolin/IBMX), 10 μM Forskolin/100 μM IBMX for 1 h; PI3K inhibitor 2 (LY294002), 10 μM for 4 h; LPA, 10 μM for 1 h; Sphin gosine1-phosphophate (S1P), 1 μM for 1 h; 12- O -tetradecanoylphorbol-13-acetate (TPA), 5 nM for 1 h; 2-deoxy glucose, 25 mM for 1 h. Biosensor activity was determined by luciferase assay or BLI of live cells ( n = 3). f , g LATS-BS can be used to observe LATS activity under the microscope. LATS-BS was stably overexpressed in A549 and MDA-MB231. Cells were imaged using LV200 BLI. Images in g are higher magnification of images in f . Scale bar represents 100 μm ( f ) or 20 μm ( g ). h LATS-BS can be used to determine LATS activity in vivo. HEK293 were transfected with LATS-BS. Cells were injected into the mammary fat pad of immunocompromised mice. After 48 h, BLI was performed. Data are represented as mean ± SD

    Article Snippet: The following compound treatments were used for in vitro luciferase assay and live-cell imaging: RAF inhibitor (GW5054, Cayman Chemical), ATR inhibitor (CGK733, Cayman Chemical), PI3K inhibitor 1 (GDC0941, Cayman Chemical), PI3K inhibitor 2 (LY294002, Cayman Chemical), PDK inhibitor (GSK2334470, Cayman Chemical)—10 μM for 4 h, EGF- 100 ng ml−1 for 1 h; insulin (Sigma 91077 C)—10 μg ml−1 for 1 h; F/IBMX (Forskolin, Cayman Chemical /IBMX, Cayman Chemical)—0.1–10 μM for Forskolin and 100 μM for IBMX for 1 h; L-α–LPA (Sigma L7260)—0.1–10 μM for 1 h, S1P-1 μM for 1 h; TPA (Cell signaling #41745)—5 nM for 1 h; and 2-deoxy glucose (Sigma #D8375)—25 mM for 1 h. For the LV200 imaging, 3.5 mM d -luciferin was added to the media culturing HEK293, A549, or MDA-MB231 cells stably expressing LATS-BS at 5–10 min before imaging.

    Techniques: Activity Assay, In Vitro, In Vivo, Transfection, Multiple Displacement Amplification, Luciferase, Imaging, Microscopy, Stable Transfection, Injection, Mouse Assay

    BML-111 decreased TGF-β1-induced NIH3T3 cell α-SMA expression in a dose-dependent manner. (A) NIH3T3 cells express rs1 and (B) FPR2. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (1, 10, 100, 200 and 500 nM) for 30 min and then treated with TGF-β1 (5 ng/ml) for 24 h. (C) The expression of α-SMA was assessed using western blotting and (D) quantified. Similar results were obtained from at least 3 sections. Data are expressed as the mean ± standard deviation. # P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 decreased TGF-β1-induced NIH3T3 cell α-SMA expression in a dose-dependent manner. (A) NIH3T3 cells express rs1 and (B) FPR2. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (1, 10, 100, 200 and 500 nM) for 30 min and then treated with TGF-β1 (5 ng/ml) for 24 h. (C) The expression of α-SMA was assessed using western blotting and (D) quantified. Similar results were obtained from at least 3 sections. Data are expressed as the mean ± standard deviation. # P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Expressing, Western Blot, Standard Deviation

    BML-111 treatment inhibited α-SMA expression and ECM deposition in lungs following BLM injection. Mice treated with 50 µ l saline (Sham group) or 2 mg/kg BLM (untreated group, BML-111 group and BOC-2 group) at day 0 were intraperitoneally injected with 1 ml saline (Sham and untreated group) or 1 mg/kg of BML-111 (BML-111 group and BOC-2 group) with or without 50 µ g/kg BOC-2 (BOC-2 group) every other day from day 0-21. Mice were sacrificed on day 21 and the expression of (A and B) α-SMA and (C) fibronectin was detected using western blotting. (D) Total collagen protein was measured using a Sircol collagen assay kit, and the content of (E) hydroxyproline was determined using a Hydroxyproline assay kit. Data are expressed as mean ± standard deviation. ## P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 treatment inhibited α-SMA expression and ECM deposition in lungs following BLM injection. Mice treated with 50 µ l saline (Sham group) or 2 mg/kg BLM (untreated group, BML-111 group and BOC-2 group) at day 0 were intraperitoneally injected with 1 ml saline (Sham and untreated group) or 1 mg/kg of BML-111 (BML-111 group and BOC-2 group) with or without 50 µ g/kg BOC-2 (BOC-2 group) every other day from day 0-21. Mice were sacrificed on day 21 and the expression of (A and B) α-SMA and (C) fibronectin was detected using western blotting. (D) Total collagen protein was measured using a Sircol collagen assay kit, and the content of (E) hydroxyproline was determined using a Hydroxyproline assay kit. Data are expressed as mean ± standard deviation. ## P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Expressing, Injection, Mouse Assay, Western Blot, Sircol Collagen Assay, Hydroxyproline Assay, Standard Deviation

    BML-111 treatment improved mortality after BLM instillation. Mice received intratracheal injection of 50 µ l of saline (Sham group) or BLM 2 mg/kg (for untreated group, BML-111 group and BOC-2 group). Mice were treated intraperitoneally with the saline (for Sham group and untreated group) 1 ml or BML-111 (for BML-111 group and BOC-2 group) 1 mg/kg every other day from days 0 to 21, and BOC-2 group were given 50 µ g/kg BOC-2 30 min before the addition of BML-111, and monitored daily for survival. Data are analyzed by Kaplan-Meier method (n=10 for the Sham group and n=22 for the others). * P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 treatment improved mortality after BLM instillation. Mice received intratracheal injection of 50 µ l of saline (Sham group) or BLM 2 mg/kg (for untreated group, BML-111 group and BOC-2 group). Mice were treated intraperitoneally with the saline (for Sham group and untreated group) 1 ml or BML-111 (for BML-111 group and BOC-2 group) 1 mg/kg every other day from days 0 to 21, and BOC-2 group were given 50 µ g/kg BOC-2 30 min before the addition of BML-111, and monitored daily for survival. Data are analyzed by Kaplan-Meier method (n=10 for the Sham group and n=22 for the others). * P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Mouse Assay, Injection

    BML-111 treatment mitigated the destruction of lung architecture and production of TGF-β1, TNF-α and IL-1β in BALF following BLM iniection. Mice were treated with 50 µ l saline (Sham group) or 2 mg/kg BLM (untreated group, BML-111 group and BOC-2 group) at day 0 were intraperitoneally administered with 1 ml of saline (Sham group and untreated group) or 1 mg/kg of BML-111 (BML-111 group and BOC-2 group) in the presence or absence of 50 µ g/kg BOC-2 (BOC-2 group) prior to the administration of BML-111. Mice were then sacrificed on day 21 and the extent of pulmonary injury and fibrosis were assessed using (A) H E and (B) Masson’s trichrome staining (magnification, ×100). (C) Fibrotic score was measured using the Ashcroft method. Levels of (D) TGF-β1, (E) TNF-α and (F) IL-1β in BALF were determined using ELISA. Data are expressed as mean ± standard deviation (n=8). ## P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 treatment mitigated the destruction of lung architecture and production of TGF-β1, TNF-α and IL-1β in BALF following BLM iniection. Mice were treated with 50 µ l saline (Sham group) or 2 mg/kg BLM (untreated group, BML-111 group and BOC-2 group) at day 0 were intraperitoneally administered with 1 ml of saline (Sham group and untreated group) or 1 mg/kg of BML-111 (BML-111 group and BOC-2 group) in the presence or absence of 50 µ g/kg BOC-2 (BOC-2 group) prior to the administration of BML-111. Mice were then sacrificed on day 21 and the extent of pulmonary injury and fibrosis were assessed using (A) H E and (B) Masson’s trichrome staining (magnification, ×100). (C) Fibrotic score was measured using the Ashcroft method. Levels of (D) TGF-β1, (E) TNF-α and (F) IL-1β in BALF were determined using ELISA. Data are expressed as mean ± standard deviation (n=8). ## P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Mouse Assay, Staining, Enzyme-linked Immunosorbent Assay, Standard Deviation

    BML-111 suppressed TGF-β1-induced NIH3T3 cell activation. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (200 nM) for 30 min in the absence or presence of BOC-2 (10 µ M; administered 30 min prior to BML-111 treatment) and then stimulated with TGF-β1 (5 ng/ml) for 24 h. (A) The protein expression of α-SMA and fibronectin and the results of the western blot analysis quantified for (B) α-SMA and (C) fibronectin; and (D) total collagen concentration and (E) cell viability were assessed. Data are presented as the mean ± standard deviation for three independent experiments. # P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 suppressed TGF-β1-induced NIH3T3 cell activation. Cells were pretreated with a vehicle (0.035% ethanol) or BML-111 (200 nM) for 30 min in the absence or presence of BOC-2 (10 µ M; administered 30 min prior to BML-111 treatment) and then stimulated with TGF-β1 (5 ng/ml) for 24 h. (A) The protein expression of α-SMA and fibronectin and the results of the western blot analysis quantified for (B) α-SMA and (C) fibronectin; and (D) total collagen concentration and (E) cell viability were assessed. Data are presented as the mean ± standard deviation for three independent experiments. # P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Activation Assay, Expressing, Western Blot, Concentration Assay, Standard Deviation

    BML-111 inhibited TGF-β1-induced NIH3T3 cell Smad-dependent and Smad-independent signaling. NIH3T3 cells were stimulated using 5 ng/ml TGF-β1 in the absence or presence of 200 nM BML-111 (added 30 min prior to experimentation). Levels of (A) Smad2/3 and phosphorylated (B) Smad2/(C) Smad3 were assessed. (D) ERK and (E) phosphorylated ERK, (F) Aktand (G) phosphorylated Aktwere also analyzed using western blotting, 24 h following cell stimulation. The figures are representative results of three independent experiments. Data are expressed as mean ± standard deviation. ## P

    Journal: International Journal of Molecular Medicine

    Article Title: BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo

    doi: 10.3892/ijmm.2018.3914

    Figure Lengend Snippet: BML-111 inhibited TGF-β1-induced NIH3T3 cell Smad-dependent and Smad-independent signaling. NIH3T3 cells were stimulated using 5 ng/ml TGF-β1 in the absence or presence of 200 nM BML-111 (added 30 min prior to experimentation). Levels of (A) Smad2/3 and phosphorylated (B) Smad2/(C) Smad3 were assessed. (D) ERK and (E) phosphorylated ERK, (F) Aktand (G) phosphorylated Aktwere also analyzed using western blotting, 24 h following cell stimulation. The figures are representative results of three independent experiments. Data are expressed as mean ± standard deviation. ## P

    Article Snippet: Mice were randomly divided into 4 groups: A saline-injected group (sham group; n=10), a BLM-injected group treated with saline (untreated group; n=22), a BLM intratracheal injection group treated with BML-111 (BML-111 group; n=22), and a BOC-2 group (n=22).

    Techniques: Western Blot, Cell Stimulation, Standard Deviation